NATICK, Mass., March 7, 2011 /PRNewswire/ — Boston Scientific
Corporation (NYSE:
BSX) today announced it has received CE Mark for its
OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System,
the Company’s third-generation coronary stenting technology.
It incorporates Boston Scientific’s unique platinum chromium
(PtCr) alloy designed specifically for coronary stenting and is
intended to provide interventional cardiologists with a bare-metal
stent with improved acute performance in treating patients with
coronary artery disease. The Company will immediately begin
marketing the OMEGA Stent System in the European Union and other CE
Mark countries.
“In my experience, the platinum chromium alloy and design used
in the OMEGA Stent offer excellent deliverability, visibility and
conformability while improving radial strength and reducing stent
recoil,” said Antonio Colombo, M.D., Director of the Cardiac
Catheterization Laboratory at Columbus Hospital and San Raffaele
Hospital in Milan, Italy. “The OMEGA Stent and platinum
chromium alloy offer meaningful performance improvements without
the tradeoffs associated with older stent alloys.”
The OMEGA Stent System is part of Boston Scientific’s PtCr Stent
series, which includes the TAXUS® Element™
Paclitaxel-Eluting Stent System and PROMUS Element™
Everolimus-Eluting Stent System. All three stents feature the
novel PtCr alloy and an innovative stent design, which combine to
offer greater radial strength and flexibility while reducing stent
recoil. The higher density alloy provides superior visibility
while permitting thinner struts compared to prior-generation
stents(1). The enhanced delivery system features a dual-layer
balloon and is engineered to improve access to challenging
lesions.”The platinum chromium PROMUS Element and TAXUS Element
Stents have been well rec
‘/>”/>
